Angiodynamics Inc

  • Earnings Score
  • Moat Score
  • Market Cap $350.02M
  • PE -1
  • Debt $NaN
  • Cash $55.01M
  • EV $NaN
  • FCF -$23.33M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$243.03M
EBIT-$239.33M
ROE-124%
ROA-82%
FCF-$23.33M
Equity$196.58M
Growth Stability-605%
PE-1.44
PB1.78
P/FCF-15
P/S1.2
Price/Cash0.16
Net Margins-19%
Gross Margins52%
Op. Margins-82%
Earnings CAGR1%
Sales Growth YoY-14%
Sales Growth QoQ-5%
Sales CAGR-1%
FCF CAGR-3%
Equity CAGR-7%
Earnings Stability0
Earnings Growth YoY-128%
Earnings Growth QoQ-5%
Sales CAGR 5Y7%
FCF CAGR 5Y4%
Equity CAGR 5Y-16%
Earnings CAGR 3Y-0%
Sales CAGR 3Y-0%
Equity CAGR 3Y-24%
Market Cap$350.02M
Revenue$292.73M
Assets$293.63M
Cash$55.01M
Shares Outstanding40.65M
Earnings Score6%
Moat Score2%
Working Capital95.9M
Current Ratio2.25
Gross Profit$151.36M
Shares Growth 3y2%
Equity Growth QoQ-4%
Equity Growth YoY-54%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, it derives a majority of revenue from the United States.

SEC Filings

Direct access to Angiodynamics Inc (ANGO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Aug 31
    • 10-K May 31
    • 10-Q Feb 29
  • 2023
    • 10-Q Nov 30
    • 10-Q Aug 31
    • 10-K May 31
    • 10-Q Feb 28
  • 2022
    • 10-Q Nov 30
    • 10-Q Aug 31
    • 10-K May 31
    • 10-Q Feb 28

Sector Comparison

How does Angiodynamics Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Angiodynamics Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%
Stability 0%
loading chart...

Angiodynamics Inc Discounted Cash Flow

Fully customizable DCF calculator online for Angiodynamics Inc.

= -$188M
012345678910TV
fcf-$23M-$23M-$22M-$21M-$20M-$20M-$19M-$18M-$18M-$17M-$17M-$167M
DCF-$21M-$18M-$16M-$14M-$12M-$11M-$9.5M-$8.3M-$7.3M-$6.5M-$65M
Value-$188M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years05/201505/201605/201705/201805/201905/202005/202105/202205/202305/2024TTM
Net Margins-1%-12%1%5%23%-63%-11%-8%-15%-61%-19%
ROA-0%2%1%-1%-28%-6%-5%-10%-60%-82%
ROE--9%1%3%10%-37%-7%-6%-14%-90%-124%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years05/201505/201605/201705/201805/201905/202005/202105/202205/202305/2024TTM
Debt over FCF-0.381.942.514.08-0--2.18-13.34-0-
Debt over Equity0.020.030.20.180.230-0.060.130-
Growth Stability------605%-----605%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years05/201505/201605/201705/201805/201905/202005/202105/202205/202305/2024CAGR 5Y
Revenue YoY growth--1%-1%-2%-21%-2%10%9%7%-10%7%
Earnings YoY growth-1K%-111%226%276%-372%-81%-16%98%252%-
Equity YoY growth--7%2%5%13%-26%-3%-3%-11%-46%-16%
FCF YoY growth-200%23%-26%-12%-163%-187%-161%-68%722%4%